ANALYTICA ANNOUNCES EXPANSION OF PERICOACH® PELVIC HEALTH SOLUTION INTO CHINA
• PeriCoach will be distributed through extensive network of postpartum care centres, hospitals, pharmacy chains, and online platforms serviced by the joint venture partners.
• Joint venture will also leverage extensive network of over 30,000 clinicians in 100 cities to distribute PeriCoach in China.
• Agreement builds upon Analytica’s existing Middle East distribution partnership to facilitate growth and manufacturing of PeriCoach in international markets.
• Clinical trial confirms unsupervised PeriCoach treatment is on par with in-clinic pelvic floor physical therapy for treating stress urinary incontinence, at a much lower cost.
• PeriCoach provides cost-effective solution to improve quality of life, ease burden of care and reduce incontinence pad expenditure in postpartum and aging populations.
BRISBANE, Australia, April 1 (Bernama-GLOBE NEWSWIRE) -- Analytica Limited (ASX:ALT), the Australian manufacturer of the PeriCoach pelvic floor exercise system for the treatment of stress urinary incontinence, has entered into a joint venture (JV) agreement to manufacture, distribute and market the system in China, Macau, Hong Kong and Taiwan. Analytica partners with Hebei NACOL Bio-Technology Co., Ltd (Nacol) and Shijiazhuang Biosphere Pty Ltd (Biosphere), based in Hebei Province.
Nacol key shareholders include two highly experienced Chinese medical manufacturing and distribution companies, Heibei Aineng Biological Technology Co., Ltd and Shijiazhuang YST Medical Supplies Co. Ltd.
The JV will register PeriCoach with the Chinese Food and Drug Administration (CFDA) as a class II medical device. With CFDA clearance, PeriCoach can become a prescription treatment, initially covering the hospital network in the North China area.
Expansion into China will support the distribution of PeriCoach to both the rapidly growing postpartum rehabilitation market and the early-stage preventative senior market, as one in three women worldwide suffer from stress urinary incontinence. The agreement furthers Analytica’s strategy to bring PeriCoach into global markets, building upon growth in the Middle East with partner Motion Egypt LLC, and pursuit of other partners in North America, Europe and Southeast Asia outside of China.
PeriCoach is comprised of a medical device, smartphone app and the PeriVault, the largest pelvic floor muscle exercise database in the world. PeriCoach includes biofeedback technique guidance technology that helps women correctly perform pelvic floor exercises, also known as “Kegel” exercises, while the device and app are being used. Real-world data from PeriCoach patients¹ shows that nearly 60% of women do not know how to engage these hidden muscles when they first use the device. PeriCoach technique guidance means “Kegels” can be done correctly and confidently by any woman in the privacy of her own home.
A recent independent, peer-reviewed, randomized controlled clinical trial²,³ performed at the University of New Mexico and published in the Journal of Female Pelvic Medicine & Reconstructive Surgery concluded that the PeriCoach biofeedback system, with no formal instruction, is non-inferior and on par with in-clinic pelvic floor physical therapy in a pelvic floor centre of excellence, making this system the most cost-effective⁴ form of treatment for stress and mixed urinary incontinence. Watch Video Here.
A photo accompanying this announcement is available at:
Currently manufactured in Australia, the new PeriCoach manufacturing line for the Chinese market only is located in the Shijiazhuang Free Trade Zone and will be listed as one of the major projects in the free trade zone and high technology zone.
PeriCoach will be distributed through the existing extensive network of hospitals and postpartum organisations serviced by the JV partners. The JV partners have collaborated with a leading postpartum care service platform in China with coverage of 100 cities and more than 30,000 clinical professionals.
In China, 15 million babies are born each year.⁵ With the rapid development of the modern economy, the postpartum rehabilitation industry has grown to 3.95bn yuan pa (US$608M) in 2018, with a compound annual growth rate of 43.9%.⁶
Furthermore, China, as with Western countries, has an aging population among which 31% of older women experience urinary incontinence, but only 25% of those currently seek medical assistance.⁷ The JV sees a large public health opportunity for conservative treatment of incontinence in women aged 50-70 years, reducing the quality-of-life impact along with the longer-term economic burden of aged-care.
http://mrem.bernama.com/viewsm.php?idm=39708
Comments